New York, NY – December 21, 2018 Kali, Inc. (USOTC: KALY) executed a reverse merger last month acquiring a patented cannabis extraction asset. As the company cleans up its filings and updates its website, it is becoming clear that there is a lot here under the hood. Not only does the company have a patented cannabis extraction process, it has a substantial amount of research behind cannabis extracts derived from the patented extraction process. The company just release news this week (see below) on research conducted with Beach Tree Labs and Brown University for a cannabis extract therapy for respiratory diseases. This research was intended as an example of more research yet to be disclosed. The news indicated further research study information would be forthcoming. The company has already attracted the attention of Generex Biotechnology (OTCQB: GNBT) that has FDA trials underway with the likes of Merck (NYSE: MRK). If KALY’s partnership with GNBT advances to trial stage or if GNBT signs a second pharmaceutical company, KALY can arguably justify a $100 million valuation and $0.10 PPS. Even now, with preclinical research results for a respiratory condition with an $11 billion therapy market, where a 1 percent penetration of that market would be over $1 billion dollars, KALY can justify a higher valuation today than the current PPS. Comparing KALY to other OTC quoted biotechs; taking into account the OTC transparency concerns, but also considering the $400,000 in revenue contracts (see below) KALY has recently announced, a $0.05 PPS today does not seem out of the question.
KALY Short Squeeze
The KALY PPS has gone in the last month from $0.003 to over $0.03. As with any such meteoric, the trading has attracted its fair share of short sellers. In fact, KALY has been reported all week as one of the top 11 most shorted stocks on the OTC. Yesterday, the PPS dropped below $0.02 as a result of a short raid, but not on a lot of volume. The PPS popped at the open today almost going back to $0.03. There is definitely a short squeeze here and if all that KALY has under the hood gets a little more market attention, the short cover will contribute to pushing the KALY PPS to the $0.05 it arguably deserves today and maybe even higher.
US Cannabis Health
KALY is partners with Puration, Inc. (USOTC: PURA) and Nouveau Life Pharmaceuticals, Inc. (USOTC: NOUV) in a joint venture named US Cannabis Health for the purpose of together developing partnerships with pharmaceutical companies to develop cannabis pharmaceuticals. US Cannabis Health recently announced its first agreement with Generex Biotechnology, Corp. (OTCQB: GNBT).
Learn more about Kali, Inc. at www.kali-extracts.com.
NextBigTicker.com (NBT)is a third party publisher and news dissemination service provider. NBT is NOT affiliated in any manner with any company mentioned herein. NBT is news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. NBT's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release or opinion of the writer. NBT is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. NBT has not been compensated for this release and HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur.